ProCE Banner Activity

CE / CME

Optimizing the Use of BTK Inhibitors in B-Cell Malignancies: Insights for the Multidisciplinary Team—Downloadable Webcast

Multimedia
In this on-demand Webcast, John Allan, MD, reviews available evidence on the use of BTK inhibitors for chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies.

Physicians : maximum of 1.00 AMA PRA Category 1 {Credit}

Pharmacists : 1.00 contact {hour} ({0.1} CEUs)

Released: July 08, 2019

Expiration: July 08, 2020

No longer available for credit.

Share

Faculty

Christopher R. Flowers

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Andrew D. Zelenetz

Andrew D. Zelenetz, MD, PhD

Associate Professor, Department of Medicine
Cornell University Medical College
Chief, Lymphoma Service
Memorial Sloan-Kettering Cancer Center
New York, New York

John N. Allan

John N. Allan, MD

Associate Professor of Clinical Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

Provided by

Provided by Purdue University College of Pharmacy
ProCE Banner

Supporters

This activity is supported by an educational grant from

AstraZeneca

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with mantle cell lymphoma, chronic lymphocytic leukemia, or Waldenström’s macroglobulinemia.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Compare and contrast efficacy and adverse event profiles of the available and emerging BTK inhibitors for the treatment of B-cell malignancies
  • Plan optimal therapeutic strategies for patients with MCL, CLL, and WM
  • Explain to patients the importance of and provide strategies for optimal adherence to prescribed oral therapies
  • Apply multidisciplinary treatment decision-making for patients with B-cell malignancies

Program Director Disclosure

Program Director

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Christopher R. Flowers, MD, MS, has disclosed that he has received consulting fees from AbbVie, Bayer, Denovo Biopharma, Gilead Sciences, Karyopharm, OptumRx, Pharmacyclics/Janssen, and Spectrum and funds for research support from AbbVie, Acerta, Burroughs Wellcome Fund, Celgene, Genentech/Roche, Gilead Sciences, Janssen, Millennium/Takeda, TG Therapeutics, and V Foundation.

Andrew D. Zelenetz, MD, PhD

Associate Professor, Department of Medicine
Cornell University Medical College
Chief, Lymphoma Service
Memorial Sloan-Kettering Cancer Center
New York, New York

Andrew D. Zelenetz, MD, PhD, has disclosed that he has received consulting fees from Adaptive Biotechnologies, Amgen, Celgene, Genentech/Roche, Gilead Sciences, Janssen, and Novartis; funds for research support from Gilead Sciences, MEI Pharma, and Roche; and has received other financial material support from BeiGene.

Faculty Disclosure

Primary Author

John N. Allan, MD

Associate Professor of Clinical Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

John Allan, MD, has disclosed that he has served on advisory boards for and received consulting fees from AbbVie, Genentech, Sunesis, Pharmacyclics, and Verastem.

Staff Disclosure

Staff

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Taryn O’Loughlin-Gross, PhD

Senior Managing Editor
Clinical Care Options, LLC

Taryn O’Loughlin Gross, PhD, has disclosed that she has received fees for non-CME services from Harmony Biosciences, Saluda Medical, and Shionogi.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Clinical Care Options, LLC. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Physician Continuing Medical Education

Credit Designation

Purdue University College of Pharmacy designates this enduring material for a maximumof 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-19-045-H01-P, 1.0 contact hours (0.1 CEU).

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 08, 2019, through July 08, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ competence in using BTK inhibitors to improve treatment outcomes for patients with mantle cell lymphoma, chronic lymphocytic leukemia, or Waldenström’s macroglobulinemia.